Thus, this study certifies and emphasizes the value of N-term hepatic mutations of AR as highly malignant oncogenic drivers in HCC and identifies their drug sensitization to the AMPK activator, which not only provides further understanding of AR in hepatocarcinogenesis but also holds promising potential as a guide for clinical treatment strategies targeting HCC patients with these specific AR mutations. The gene discussed is AR; the disease is hepatocellular carcinoma.